Lilly's tirzepatide reduced obstructive sleep apnea (OSA) severity, with up to 51.5% of participants meeting the criteria for disease resolution

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. MU
3. ACN
4. IBM
5. DPZ
6. PRIM
7. META
8. IMNN
9. NAVN

Go back to Lilly's tirzepatide reduced obstructive sleep apnea (OSA) severity, with up to 51.5% of participants meeting the criteria for disease resolution

Eli Lilly (LLY) PT Raised to $1,000 at Truist Securities

June 24, 2024 4:42 PM EDT

Truist Securities analyst Robyn Karnauskas raised the price target on Eli Lilly (NYSE: LLY) to $1,000.00 (from $892.00) while maintaining a Buy rating.

The analyst comments "We are adjusting our model estimates ahead of the quarter to reflect script growth and management commentary on the quarter.... More